GLP-1 Drugs and Jobs

Can a weight-loss injection change your career prospects? For unemployed women, the answer increasingly looks like yes.

A new study from Harvard economist Rebecca Diamond found something striking. Women who started taking GLP-1 medications while unemployed saw their odds of landing a job jump by 27 percentage points within 18 months. That’s compared to women who wanted the drugs but hadn’t started treatment yet.

The research builds on something scientists have documented for years: the “obesity penalty.” Heavier women tend to earn less. They also face more roadblocks in the hiring process than their thinner counterparts do.

So how do these drugs actually work? GLP-1 medications like semaglutide and tirzepatide mimic hormones your body already makes. These hormones control appetite, slow digestion, and help regulate insulin. The FDA has approved several versions specifically for weight management, as well as others for type 2 diabetes. All of them require a prescription, and doctors usually recommend pairing them with diet and lifestyle changes for the best results.

Diamond pulled her data from the Understanding America Study, a large, nationally representative survey. She compared unemployed women who began GLP-1 treatment against similar women who hadn’t started yet. The pattern that emerged was clear and consistent.

Most of the employment gains came from women moving out of unemployment entirely, not from people returning to work after retirement or disability. Interestingly, the drugs seemed to reshape more than just job prospects. Marriage and cohabitation rates among treated women rose by 29 percentage points over the same 18-month period.

But here’s where it gets more complicated. Women who already had jobs before starting GLP-1 treatment didn’t see any career boost at all. No raises. No promotions. Nothing measurable.

That gap tells us something important. Weight-based bias seems to hit hardest during the hiring process itself, not after someone’s already in the door. Earlier research backs this up too. Obese women get fewer callbacks after job interviews, and they often earn less than their peers once employed. Diamond didn’t respond to a request for comment on her findings.

There’s also a bigger, thornier issue lurking behind these numbers: access. Not everyone can afford these drugs, and that matters.

By the end of 2024, roughly 6% of women had started using a GLP-1 medication for weight loss. Among women with a history of obesity, that number climbed to 9%. Diamond pointed out that early adopters tend to be financially better off, which makes sense given the price tag involved.

Without insurance, brand-name GLP-1 drugs can cost more than $1,000 a month. That’s simply out of reach for a lot of people. Meanwhile, coverage under federal programs like Medicare and Medicaid remains inconsistent, and policy debates over expanding access are ongoing.

So what does this mean going forward? If losing weight through medication genuinely improves how women are treated in the job market, then unequal access to these drugs could end up deepening existing inequalities rather than fixing them. It raises an uncomfortable question too: should a medical treatment really be the fix for workplace discrimination based on someone’s size? That’s a question employers, insurers, and policymakers are only beginning to grapple with.